Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients With Acute Coronary Syndrome in a Real-world Registry - Trial NCT05774431
Access comprehensive clinical trial information for NCT05774431 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital Heidelberg and is currently Recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 6789 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital Heidelberg
Timeline & Enrollment
N/A
Mar 13, 2023
Dec 30, 2023
Primary Outcome
Comparison of Eligible Patients for Dual Antiplatelet Therapy: ASS and Ticagrelor vs ASS and Prasugrel
Summary
The primary objective of this study is to compare patients eligible for ASS and Ticagrelor
 against those eligible for ASS and Prasugrel. The available information regarding relative
 and absolute exclusion criteria outlines reasons for disqualification from either drug.
 
 The secondary objectives of the study are to:
 
 - Assess the proportion of patients who received ASS and Ticagrelor in the study cohort.
 
 - Compare the proportion of patients who received ASS and Ticagrelor against the
 proportion of patients who qualify for DAPT with ASS and Ticagrelor (eligible group).
 
 - Describe the antithrombotic treatment, including antiplatelet monotherapies, and
 antiplatelet therapies with or without anticoagulation.
 
 The investigators will use these objectives to evaluate the effectiveness and appropriateness
 of the different antiplatelet therapies in the study population. Participants will not be
 personally identified in any reports or publications resulting from this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05774431
Non-Device Trial